Four questions to predict cognitive decline in de novo Parkinson’s disease
Early identification of cognitive decline (CD) in de novo Parkinson's disease (PD) is crucial for choosing appropriate therapies and recruiting for clinical trials. However, existing prognostic models lack flexibility, scalability and require costly instrumentation. This study explores the utility of standard clinical questionnaires and criteria to predict CD in de novo PD. A total of 186 patients from the Parkinson Progression Markers Initiative (PPMI) and 48 patients from the Biomarkers of Parkinson's Disease project (BIO-PD) underwent clinical interviews, comprehensive tests, and questionnaires. A model based only on age of disease onset, history of stroke, history of fainting, and vocalization during dreams predicted CD in 2 and 4-year horizons with an area under curve (AUC) of 70% ± 10% standard deviation (cross-validated PPMI), 79% (overall PPMI), and 78% (validation in BIO-PD). This approach enables rapid preliminary screening using just four simple questions, achieving predictive accuracy comparable to instrumentation-based methods while reducing assessment time.
Authors
- Tereza Bartošová (ORCID: https://orcid.org/0000-0003-2595-2422)
- Karel Šonka (ORCID: https://orcid.org/0000-0001-5773-9656)
- Dominik Škrabal
- Filip Havlík (ORCID: https://orcid.org/0000-0003-4442-6743)
- Petr Dušek (ORCID: https://orcid.org/0000-0003-4877-9642)
- Ondřej Bezdíček (ORCID: https://orcid.org/0000-0002-5108-0181)
- Josef Mana (ORCID: https://orcid.org/0000-0002-7817-3978)
- Jan Hlavnička (ORCID: https://orcid.org/0000-0002-8510-5535)
- Martin Čihák (ORCID: https://orcid.org/0000-0001-7765-4799)
- Evžen Růžička (ORCID: https://orcid.org/0000-0002-4893-9661)
Institutions
- Charles University (CZ)
- General University Hospital in Prague (CZ)
- Czech Technical University in Prague (CZ)
Publication Details
- Journal
- npj Parkinson s Disease
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1038/s41531-025-00958-5
- Citations
- 1
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Eli Lilly and Company
- Pfizer
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Celgene
- Jazz Pharmaceuticals
- Neurocrine Biosciences
- Verily Life Sciences
- Voyager Therapeutics
- European Commission
- Agentura Pro Zdravotnický Výzkum České Republiky
- Servier
- H. Lundbeck A/S
- Sun Pharma
- Genentech
- Allergan
- Avid Radiopharmaceuticals